Artificial Intelligence

Global Generic Drugs Market to Reach $671.5 Billion by 2030

Published

11 months ago

May 25, 2023

<!– Name:DistributionId Value:8846568 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:7bcf4a19-7bf1-4235-bb94-5ce9c2971bac –>

New York, May 25, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Generic Drugs Industry” – https://www.reportlinker.com/p06041415/?utm_source=GNW
Small-Molecule Generics, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$538.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biosimilars segment is readjusted to a revised 19.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $122.8 Billion, While China is Forecast to Grow at 8.2% CAGR

The Generic Drugs market in the U.S. is estimated at US$122.8 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$126.8 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Select Competitors (Total 255 Featured)
– Astellas Pharma, Inc.
– Biocon Ltd.
– 3SBio, Inc.
– Arbor Pharmaceuticals LLC
– AristoPharma Ltd.
– Breckenridge Pharmaceutical, Inc.
– Amphastar Pharmaceuticals, Inc.
– Advance Pharmaceutical Inc.
– Celltrion, Inc.
– Acadia Pharmaceuticals, Inc.
– Acino International AG
– Acella pharmaceuticals
– Argentum Pharmaceuticals
– AustarPharma, LLC
– API Pharma Tech

Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and Global Economic Update
From Pandemic to War & Inflation: ?Gloomy Outlook for 2023
Despite Signs of Easing Inflationary Conditions
Here?s How Inflationary Pressures Affect the Economy
Russia-Ukraine War, the Primary Culprit Responsible for the
Hardships
Although Past Peak in 2023, Efforts to Solve the Inflation
Puzzle Should Continue
Here?s What?s Causing Inflationary Pressures in the Global Market
Shaken by the War, Global Oil Prices Spiral and Feed
Inflationary Pressures, Guiding the World Towards a Cost of
Living Crisis: Global Average Annual Brent Crude Oil Price
(In US$ Per Barrel) for Years 2017 through 2024
War-Induced Commodity Price Increases & Broad Based Price
Pressures Mark the Return of Global Inflation to the Highest
Level Seen Since 1996: Global Inflation Rates (In %) for the
Years 2019 Through 2024
Although Facing a Lower Recession Risk, Global Economic Growth
in 2023 to Slowdown Amid War, Inflation, Elevated Interest
Rates & Marginal Easing of Inflation: World Economic Growth
Projections (Real GDP, Annual % Change) for the Years 2020
Through 2024
Recession Triggered by Uncontrolled Inflation or Unemployment,
Which is the Greater Evil? Inflation Battling Policy Measures
to Slowdown Post Pandemic Recovery in Unemployment Rates:
Global Number of Unemployed People (In Million) for Years
2019 Through 2024
How the Healthcare Industry Has Been Impacted by the Pandemic &
What?s the New Normal?
With the COVID-19 Pandemic Exposing Global Healthcare
Unpreparedness, There is Increasing Policy Led Focus on
Rebooting Health Systems Worldwide: Current & Required
Healthcare Spending as % of GDP
COVID-19 Impact on Global Pharmaceutical Supply Chain and
Generic Drugs Market
Demand for Generic Pain Killers Rises
A Prelude to Generic Drugs
Generic Drugs Market Set for a Rapid Growth
North America and Europe Dominate, Asia-Pacific to Exhibit the
Fastest Growth
India- A Significant Market
Small-molecule Generic Drugs Account for a Lion’s Share,
Biosimilars Exhibit Fastest Growth
Exciting Times for Biosimilars
Competition
Generic Drugs – Global Key Competitors Percentage Market Share
in 2023 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2023 (E)
Market Opportunities
Strategies to Sustain Success
The Future of Generics & Biosimilars Look Bright amid
Persistent Barriers
Market Challenges
Factors Affecting Prices & Accessibility
Recent Market Activity
BRANDS

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Generic Drugs Enjoy Adrenaline Rush with Regulatory &
Scientific Support
R&D & Innovation Push
Efforts to Eliminate Barriers to Generics Development
Regulatory & Scientific Collaboration as Key
FDA?s Generic Drug User Free Program
Policy Support to Generic Drugs: Clearing Road to Affordable
Access to Quality Medicines
Savings in Billions
Taking GDUFA to Next Level
Pushing Competition through ANDAs
Major Push to COVID-19 Drugs
Patent Expiries Set to Widen the Addressable Market for Generic
Drugs
Patent Expiries of Select Drugs in 2020
Patent Expiries of Select Drugs in 2021
Patent Expiries of Select Drugs in 2022
Patent Expiries of Select Drugs in 2023
Patent Expiry of Select Major Drugs in the US: 2020-2023
Robust Demand for Pharmaceutical Drugs Drives Demand for
Generic Drugs
Cost Containment Measures Put Focus on Generics
Small Molecule Generics Represent the Dominant Segment
Specialty Generic Drugs Gain Popularity
Specialty Generics – The Way to Success Amid Challenges
Factors that can Provide Competitive Edge
Increasing Demand for Biosimilars, Driven by Patent Expiry of
Major Biopharmaceutical Drugs
Patent Expiries of Major Biopharmaceutical Drugs in the US and
Europe in the Recent Past
Progressive Regulatory Framework Accelerates Product Approvals &
Subsequently Market Revenues
Specific Guidelines for Biosimilars in Various Countries with
Year of Publication
Biosimilars Regulatory Agencies in Select Regional Markets
Biosimilar Approvals in the US (as of 2023)
Biosimilar Approvals in Europe (as of 2023)
Rising Healthcare Costs Drive Demand for Generic Drugs
World Healthcare Expenditure (In US$ Billion) for the Years
2017-2023
Aging Population to Propel the Demand for Generic Drugs
Global Aging Population Statistics for the 65+ Age Group in
Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Significant Increase in Number of Patients Suffering from
Chronic Diseases Fuel Demand for Generic Medicines
Global Cost of Chronic Diseases (In US$ Billion) for the Years
2018 and 2030
Fatalities by Heart Conditions – Estimated Percentage Breakdown
for Cardiovascular Disease, Ischemic Heart Disease, Stroke,
and Others
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Number of New Cancer Cases and Deaths (in Million) by Region
for 2018
US Regulators Struggle to Keep Up with the Global Market
Increased Dependency on Non-US Manufacturers
Patient Trust and Traceability
Drug Supply Shortage Risks
Fixing a Broken System
Hospitals Teaming Up to Develop Own Generic Drugs to Combat
Shortages and High Prices
Use of Artificial Intelligence and Machine Learning in
Pharmaceutical Manufacturing Witnesses a Surge

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Generic Drugs Market Analysis of Annual Sales in
US$ Million for Years 2018 through 2030

Table 2: World Recent Past, Current & Future Analysis for
Generic Drugs by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 3: World Historic Review for Generic Drugs by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR

Table 4: World 12-Year Perspective for Generic Drugs by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2018, 2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for
Small-Molecule Generics by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 6: World Historic Review for Small-Molecule Generics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR

Table 7: World 12-Year Perspective for Small-Molecule Generics
by Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030

Table 8: World Recent Past, Current & Future Analysis for
Biosimilars by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 9: World Historic Review for Biosimilars by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR

Table 10: World 12-Year Perspective for Biosimilars by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for
Cardiovascular by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 12: World Historic Review for Cardiovascular by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR

Table 13: World 12-Year Perspective for Cardiovascular by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030

Table 14: World Recent Past, Current & Future Analysis for
Central Nervous System (CNS) by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 15: World Historic Review for Central Nervous System
(CNS) by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR

Table 16: World 12-Year Perspective for Central Nervous System
(CNS) by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2018, 2023 &
2030

Table 17: World Recent Past, Current & Future Analysis for
Dermatology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 18: World Historic Review for Dermatology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR

Table 19: World 12-Year Perspective for Dermatology by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030

Table 20: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 21: World Historic Review for Oncology by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR

Table 22: World 12-Year Perspective for Oncology by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2018, 2023 & 2030

Table 23: World Recent Past, Current & Future Analysis for
Respiratory by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 24: World Historic Review for Respiratory by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2021 and
% CAGR

Table 25: World 12-Year Perspective for Respiratory by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2018, 2023 & 2030

Table 26: World Recent Past, Current & Future Analysis for
Other Therapeutic Applications by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 27: World Historic Review for Other Therapeutic
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2018 through 2021 and % CAGR

Table 28: World 12-Year Perspective for Other Therapeutic
Applications by Geographic Region – Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2018, 2023 & 2030
A Prelude to Generic Drugs

III. MARKET ANALYSIS

UNITED STATES
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in the United States for 2023 (E)
Table 29: USA Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 30: USA Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 31: USA 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 33: USA Historic Review for Generic Drugs by Therapeutic
Application – Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2018 through 2021 and % CAGR

Table 34: USA 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

CANADA
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in Canada for 2023 (E)
Table 35: Canada Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 36: Canada Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 37: Canada 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 39: Canada Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 40: Canada 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

JAPAN
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Japan Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 43: Japan 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 44: Japan Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 45: Japan Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 46: Japan 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

CHINA
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in China for 2023 (E)
Table 47: China Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: China Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 49: China 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 50: China Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 51: China Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 52: China 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

EUROPE
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in Europe for 2023 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Geographic Region – France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 54: Europe Historic Review for Generic Drugs by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2018 through 2021 and % CAGR

Table 55: Europe 12-Year Perspective for Generic Drugs by
Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2018, 2023 & 2030

Table 56: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 58: Europe 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 60: Europe Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 61: Europe 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

FRANCE
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in France for 2023 (E)
Table 62: France Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: France Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 64: France 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030

Table 65: France Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 66: France Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 67: France 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

GERMANY
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in Germany for 2023 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: Germany Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 70: Germany 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030

Table 71: Germany Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 72: Germany Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 73: Germany 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: Italy Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 76: Italy 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 77: Italy Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 78: Italy Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 79: Italy 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

UNITED KINGDOM
Generic Drugs Market Presence – Strong/Active/Niche/Trivial –
Key Competitors in the United Kingdom for 2023 (E)
Table 80: UK Recent Past, Current & Future Analysis for Generic
Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: UK Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 82: UK 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 83: UK Recent Past, Current & Future Analysis for Generic
Drugs by Therapeutic Application – Cardiovascular, Central
Nervous System (CNS), Dermatology, Oncology, Respiratory and
Other Therapeutic Applications – Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Generic Drugs by Therapeutic
Application – Cardiovascular, Central Nervous System (CNS),
Dermatology, Oncology, Respiratory and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2018 through 2021 and % CAGR

Table 85: UK 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: Spain Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 88: Spain 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule Generics
and Biosimilars for the Years 2018, 2023 & 2030

Table 89: Spain Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 90: Spain Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 91: Spain 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Generic Drugs by Type – Small-Molecule Generics and Biosimilars –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: Russia Historic Review for Generic Drugs by Type –
Small-Molecule Generics and Biosimilars Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2021 and % CAGR

Table 94: Russia 12-Year Perspective for Generic Drugs by Type –
Percentage Breakdown of Value Sales for Small-Molecule
Generics and Biosimilars for the Years 2018, 2023 & 2030

Table 95: Russia Recent Past, Current & Future Analysis for
Generic Drugs by Therapeutic Application – Cardiovascular,
Central Nervous System (CNS), Dermatology, Oncology,
Respiratory and Other Therapeutic Applications – Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 96: Russia Historic Review for Generic Drugs by
Therapeutic Application – Cardiovascular, Central Nervous
System (CNS), Dermatology, Oncology, Respiratory and Other
Therapeutic Applications Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2018 through 2021 and %
CAGR

Table 97: Russia 12-Year Perspective for Generic Drugs by
Therapeutic Application – Percentage Breakdown of Value Sales
for Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications for
the Years 2018, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Generic Drugs by Type – Small-Molecule Generics and
Biosimilars – Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 99: Rest of Europe Historic Review for Generic Drugs by
Type – Small-Molecule Generics and Biosimilars Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2021 and % CAGR

Table 100: Rest of Europe 12-Year Perspective for Generic Drugs
by Type – Percentage Breakdown of Value Sales for
Small-Molecule Generics and Biosimilars for the Years 2018,
2023 & 2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Generic Drugs by Therapeutic Application –
Cardiovascular, Central Nervous System (CNS), Dermatology,
Oncology, Respiratory and Other Therapeutic Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Generic Drugs by

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041415/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Related Topics:AI Artificial Intelligence Machine learning

Up Next

Network Security market is projected to grow at a CAGR of 16.9% by 2033: Visiongain

Don't Miss

Digital Biomanufacturing Market – Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Identity Governance & Administration Market Projected to Reach $24.42 billion by 2030 – Exclusive Report by 360iResearch

Published

5 hours ago

April 26, 2024

CISION (PR Newswire)

PUNE, India, April 25, 2024 /PRNewswire/ — The report titled “Identity Governance & Administration Market by Component (Services, Solution), Modules (Access Certification & Compliance Control, Access Management, Identity Lifecycle Management), Organization Size, Deployment, Vertical – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $8.46 billion in 2023 to reach $24.42 billion by 2030, at a CAGR of 16.34% over the forecast period.

“Navigating Global Identity Governance With Key Strategies for Digital Security and Compliance”
Identity governance and administration (IGA) has emerged as a critical policy-driven approach aimed at fortifying digital identities within organizations, ensuring that proper access is provided to the right individuals for valid reasons. Across the globe, the demand for IGA solutions is on the rise, driven by the need to tackle sophisticated cyber threats, comply with stringent data protection laws, and adapt to the digitization wave sweeping through industries. Challenges include integrating these solutions with pre-existing IT frameworks, primarily in organizations reliant on legacy systems. The North American market, led by the United States and Canada, is at the forefront of this expansion, embracing technological advancements and stringent regulatory standards. Meanwhile, the Europe, Middle East, and Africa (EMEA) region is navigating its unique landscape, with the EU focusing heavily on compliance through GDPR and the Middle East and Africa gradually recognizing the value of digital security. The Asia-Pacific region is witnessing a significant uptrend in IGA solutions adoption, spurred by digital transformation initiatives and cybersecurity awareness, with China and India playing pivotal roles. This global perspective highlights the universal importance of IGA in today’s digital era, highlighting the critical balance between innovation, security, and regulatory compliance in safeguarding digital identities.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/identity-governance-administration
“Navigating the New Normal With The Crucial Role of Identity Governance in Securing Hybrid Work Environments”
As businesses globally embrace the fusion of remote and traditional office work, the need for secure, hybrid workspaces becomes paramount. The shift toward flexible working models, accelerated by the COVID-19 pandemic, highlights the importance of cybersecurity and accessibility in ensuring operational continuity and a better work-life balance. Identity governance & administration (IGA) systems emerge as essential tools within this evolving work landscape. They enable organizations to manage digital identities and access rights effectively, safeguarding sensitive data against unauthorized access across diverse working environments. By ensuring that only credentialed employees can access critical information, regardless of their physical location, IGA solutions stand at the forefront of maintaining cybersecurity compliance and operational integrity. This development signifies a growing demand for robust identity governance frameworks, ensuring businesses remain resilient and secure in remote work and beyond.
“Elevating Security and Efficiency in Organizations through Specialized Identity Governance & Administration Services”
Managed and professional services provide organizations with the specialized expertise necessary for optimizing the performance and security of identity governance & administration (IGA) systems, eliminating the need for such in-depth knowledge internally. Businesses benefit from advanced skills that enhance system functionality and safeguard sensitive data by outsourcing specific IGA tasks. From the initial stages of integration and implementation, ensuring seamless incorporation with existing infrastructures, to ongoing support and maintenance for consistent system reliability and up-to-dateness, these services form the foundation of effective IGA strategies. Furthermore, training and consulting play a pivotal role, equipping companies with the understanding and capability to utilize their IGA systems to the fullest. IGA solution is a critical technological tool designed to streamline the management of user access rights across organizations, bolstering security, operational efficiency, and compliance with regulatory standards. This comprehensive approach to IGA facilitates a more secure, efficient, and compliant organizational environment, empowering businesses to focus on core objectives and ensure their data remains protected.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/identity-governance-administration
“International Business Machines Corporation at the Forefront of Identity Governance & Administration Market with a Strong 7.09% Market Share”
The key players in the Identity Governance & Administration Market include Broadcom, Inc., SAP SE, Oracle Corporation, Microsoft Corporation, International Business Machines Corporation, and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Identity Governance & Administration Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Identity Governance & Administration Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Identity Governance & Administration Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/identity-governance-administration
“Dive into the Identity Governance & Administration Market Landscape: Explore 197 Pages of Insights, 654 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsIdentity Governance & Administration Market, by ComponentIdentity Governance & Administration Market, by ModulesIdentity Governance & Administration Market, by Organization SizeIdentity Governance & Administration Market, by DeploymentIdentity Governance & Administration Market, by VerticalAmericas Identity Governance & Administration MarketAsia-Pacific Identity Governance & Administration MarketEurope, Middle East & Africa Identity Governance & Administration MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/identity-governance-administration
Related Reports:
Privileged Identity Management Market – Global Forecast 2024-2030Identity & Access Management Professional Services Market – Global Forecast 2024-2030Digital Identity Solutions Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/identity-governance–administration-market-projected-to-reach-24-42-billion-by-2030—exclusive-report-by-360iresearch-302126089.html

Artificial Intelligence

Enghouse Video Partners With SONIFI Health To Deliver Advanced Telehealth Solutions In Hospital Rooms

Published

11 hours ago

April 25, 2024

CISION (PR Newswire)

MARKHAM, ON, April 25, 2024 /PRNewswire/ — Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.

SONIFI Health is a leading U.S. healthcare technology company based in Sioux Falls, South Dakota. The new partnership leverages and integrates Enghouse Video room systems technology to support SONIFI Health’s commitment to expanding telehealth applications and system optimizations in hospital settings.
Enghouse’s VidyoRooms solution, a sophisticated video conferencing technology that combines both software and hardware solutions, has been fully integrated into SONIFI Health’s interactive TV systems. This integration provides up to 4K high-quality video conferencing, multi-party sessions and robust security features that ensure full compliance with healthcare regulations.
Enghouse Video offers an immersive telehealth platform to support collaborative interdisciplinary care, improved patient outcomes and cost savings. The platform is flexible and simple, delivering the reliability, interoperability, and scalability needed for today’s healthcare environment. A key strength of the partnership is its offering of back-end integrations like patient portals, medical devices, EMR, tele-sitting, remote patient observation and consultation.
“Hospitals can choose the telehealth partner that’s right for them, and we incorporate that solution with interactive TV,” said Brian Nido, SONIFI Health’s Vice President of Customer Success. “Using the hardware and systems they already have in patient rooms helps hospitals reduce costs and maximize the value of their existing investments, while benefiting both clinicians and patients.”
SONIFI Health and Enghouse Video continue to collaborate closely to further refine and enhance the telehealth solutions provided to healthcare facilities. This partnership reflects a shared commitment to leveraging technology to create smarter hospital rooms and improve patient care across the healthcare spectrum.
About Enghouse VideoEnghouse Video, part of the Enghouse Interactive division, is a subsidiary of Enghouse Systems Limited, a vertically focused software and services company traded on the Toronto Stock Exchange (TSX: ENGH). Through highly secure, scalable and flexible Cloud-based or On Prem services, we deliver one of the world’s highest quality and most innovative video platform to video-enable any application or idea. From advanced video conferencing and collaboration tools to state-of-art enterprise video management, Enghouse Video is a unique player in multiple markets, including telehealth. Learn more at www.enghousevideo.com, read our blog, or follow us on Twitter at @EnghouseVideo, on LinkedIn, and on Facebook.
About SONIFI HealthSONIFI Health provides market-leading interactive patient engagement technology proven to improve patient outcomes and staff productivity. The EHR-integrated platform is designed to enhance patient and family experiences while increasing staff satisfaction and organizations’ operational efficiencies. As part of SONIFI Solutions, Inc., the company annually supports more than 300 million end user experiences. Learn more at sonifihealth.com.
Enghouse Video Contact: Sylvain Awad, Director, Demand Generation, Enghouse Video, part of Enghouse Interactive Division, [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms-302126882.html

Artificial Intelligence

Global Insurance Provider Selects 3CLogic to Streamline AI and Contact Center Capabilities with ServiceNow

Published

17 hours ago

April 25, 2024

CISION (PR Newswire)

Multinational Insurance Broker to deploy 3CLogic’s solution with ServiceNow’s Financial Service Operations (FSO) platform to streamline customer experiences.
ROCKVILLE, Md., April 25, 2024 /PRNewswire/ — 3CLogic, the leading Conversational AI and Contact Center solution for ServiceNow®, today announced its selection by a global insurance provider to replace its existing contact center infrastructure as part of a larger CX transformation effort. The strategic decision is designed to complement the organization’s use of ServiviceNow’s Financial Services Operations (FSO) offering leveraged across a number of its existing product lines including Customer Warranty Claims, Roadside Assistance, and Home Warranties.

Serving millions of customers worldwide with innovative insurance and protective products, the organization required a solution that would enhance its recent investment in the ServiceNow platform as it works to transform its end-to-end customer service operations. The deployment will incorporate several of 3CLogic’s AI-powered capabilities purpose-built for ServiceNow, including Conversational AI, Speech Analytics, and AI Performance & Coaching, along with integrated call transcriptions, convenient 2-way SMS, and ServiceNow-centralized contact center reporting.
“We continue to see enterprises eager to complement their existing investment in digital platforms, such as ServiceNow, with contact center features purpose-built to extend the workflows and features they already have and use,” explains Matt Durkin, VP of Global Sales at 3CLogic. “It’s no secret that organizations are already juggling too many systems, often with overlapping capabilities, which impacts ROI and operational efficiency. We’re proud to offer an alternative approach that helps simplify the technology stack while optimizing the overall operational costs and outcomes.”
Recently named to Constellation Research’s 2024 Shortlist for Digital Customer Service and Support, 3CLogic has seen global adoption of its solution by leading enterprises in healthcare, manufacturing, travel, retail, higher education, finance, non-profits, and Managed Service Providers across five continents. As a ServiceNow-certified Technology and Build partner with offerings available for ServiceNow’s IT Service Management, Customer Workflows, HR Service Delivery, and Source-to-Pay solutions, the company will be unveiling its latest set of capabilities at ServiceNow’s annual Knowledge 2024 event this May in Las Vegas.
For more information, please contact [email protected].
About 3CLogic3CLogic transforms customer and employee experiences with its leading Cloud Contact Center and AI solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative features such as intelligent self-service, generative and Conversational AI, agent automation & coaching, and AI-powered sentiment analytics – all designed to lower operational costs, maximize ROI, and optimize each interaction across IT Service Desks, Customer Support, Sales or HR Services teams. For more information, please visit www.3clogic.com.
Logo – https://mma.prnewswire.com/media/2318845/3CLogic_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow-302127739.html